Amarillo CEO to present at PMS Beaver Creek on September 15

Written by Customer Service on September 10, 2020. Posted in Public Companies.

TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) — Amarillo Gold Corporation (TSXV: AGC, OTCQB: AGCBF) has recently achieved several key milestones toward developing its flagship Posse Gold Project into Brazil’s next gold mine.Mike Mutchler, President and Chief Executive Officer, will review those achievements during his presentation at the Precious Metals Summit Beaver Creek on Tuesday, September 15, 2020 at 4.30 p.m. ET. His presentation will be webcast live via the follow link:https://wsw.com/webcast/preciousmetals/agc.v/3163568.Mutchler will report on:the results of the positive feasibility study that gives Posse a net present value of US$360 million using a 5% discount rate and an after-tax internal rate of return of 50% using a gold price of US$1,730 per ounce and a Brazilian Reais to U.S. dollar exchange rate of 5.3:1progress toward...

DNO Starts Gas Capture and Injection in Kurdistan, Slashes CO2 Emissions

Written by Customer Service on September 10, 2020. Posted in Public Companies.

Oslo, 11 September 2020 – DNO ASA, the Norwegian oil and gas operator, today announced that the USD 110 million Peshkabir Gas Capture and Injection Project in its Tawke license in the Kurdistan region of Iraq is onstream and has reached the one billion cubic feet of gas injection milestone. The project is expected to reduce annual emissions from the Company’s operated production by over 300,000 tonnes of CO2 equivalent, offsetting the emissions from some 150,000 automobiles.Engineering and construction were launched in mid-2018 and commissioning completed in mid-2020 in what is the first gas capture and storage project in Kurdistan. Some 20 million cubic feet a day of previously flared gas at the Peshkabir field is gathered, treated and transported 80 kilometers by pipeline to the Tawke field where it is injected for storage and reservoir...

Oh Yes, It’s That Fast: The All-New 2021 Sea-Doo RXP-X 300 Takes Personal Watercraft Performance to Another Level

Written by Customer Service on September 10, 2020. Posted in Public Companies.

VALCOURT, Quebec, Sept. 10, 2020 (GLOBE NEWSWIRE) — There are people who love on-water performance, and then there are people who LOVE on-water performance. For those in the latter category, BRP (TSX: DOO, NASDAQ: DOOO) is launching an all-new version of its high-performance Sea-Doo RXP-X 300. Designed to be the ultimate, supercharged on-water experience, the 2021 model delivers best-in-class acceleration along with a new water-gripping hull design for incredible handling.Enhancements to the 2021 Sea-Doo RXP-X 300 start with shedding 67 pounds (30kg) from its predecessor. And a new T3-R hull with a completely revamped deep-V design provides greater stability at high speeds, something everyone from experienced weekend riders to professional racers can appreciate. It all translates into incredible performance and a more confident...

Rapide vous dites? Le tout nouveau Sea-Doo RXP-X 300 2021 fait passer les performances des motomarines au niveau supérieur

Written by Customer Service on September 10, 2020. Posted in Public Companies.

VALCOURT, Québec, 10 sept. 2020 (GLOBE NEWSWIRE) — Certaines personnes aiment les performances sur l’eau, et puis il y a les autres, celles qui AIMENT les performances sur l’eau. Pour ceux de la deuxième catégorie, BRP (TSX: DOO, NASDAQ: DOOO) lance une toute nouvelle version de son Sea-Doo RXP-X 300 hautes performances. Conçu pour offrir l’ultime expérience suralimentée sur l’eau, le modèle 2021 procure les meilleures accélérations de sa catégorie grâce à un nouveau design de coque qui adhère à la surface de l’eau pour assurer une maniabilité incroyable.Les améliorations apportées au Sea-Doo RXP-X 300 2021 commencent par une réduction de 30 kg (67 livres) par rapport à son prédécesseur. Ensuite, la nouvelle coque T3-R repensée au design en V profond est plus stable à haute vitesse, une caractéristique qu’apprécieront les conducteurs...

Kayne Anderson Midstream/Energy Fund Announces Distribution of $0.09 per Share for Q3 2020

Written by Customer Service on September 10, 2020. Posted in Public Companies.

HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) — Kayne Anderson Midstream/Energy Fund, Inc. (NYSE: KMF) (the “Fund”) announced today a quarterly distribution of $0.09 per share for the fiscal quarter ended August 31, 2020. This distribution is payable to common stockholders on September 30, 2020 (as outlined in the table below).The Fund expects the next distribution to be declared and paid in December 2020. Payment of future distributions is subject to the Board of Directors’ approval, as well as meeting the covenants of the Fund’s debt agreements and terms of its preferred stock.(1) The return of capital estimate is based on the Fund’s anticipated earnings and profits for fiscal 2020. The final determination of the tax character of distributions will be made in early 2021 and may differ substantially from this preliminary information.Kayne...

Kayne Anderson MLP/Midstream Investment Company Announces Distribution of $0.15 per Share for Q3 2020

Written by Customer Service on September 10, 2020. Posted in Public Companies.

HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) — Kayne Anderson MLP/Midstream Investment Company (NYSE: KYN) (the “Company”) announced today a quarterly distribution of $0.15 per share for the fiscal quarter ended August 31, 2020. This distribution is payable to common stockholders on September 30, 2020 (as outlined in the table below).The Company expects the next distribution to be declared and paid in December 2020. Payment of future distributions is subject to the Board of Directors’ approval, as well as meeting the covenants of the Company’s debt agreements and terms of its preferred stock.(1) The return of capital estimate is based on the Company’s anticipated earnings and profits for fiscal 2020. The final determination of the tax character of distributions will be made in early 2021 and may differ substantially from this preliminary...

Itafos Announces Commencement of Technical Studies Related to Itafos Conda Organic Growth Projects

Written by Customer Service on September 10, 2020. Posted in Public Companies.

TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) — Itafos (TSX-V: IFOS) (the “Company”) announced today that it has commenced technical studies related to Itafos Conda organic growth projects, including anhydrous hydrogen fluoride and precipitated silica (“AHF/PS”) by-product recovery and on-site ammonia production, as part of the Company’s strategic focus on optimizing Itafos Conda’s EBITDA generation capability. The Company expects to provide a further update on the respective technical studies by Q1 2021.The AHF/PS by-product recovery initiative aims at improving Itafos Conda’s EBITDA generation capability by extracting and commercializing high-value by-products AHF and PS without impacting Itafos Conda’s manufacturing process. The initiative contemplates the extraction of fluoride, in the form of silico-fluoride, from the tailings pond...

RedHill Biopharma的Opaganib显示出可完全抑制新型冠状病毒SARS-CoV-2

Written by Customer Service on September 10, 2020. Posted in Public Companies.

在人体支气管组织体外模型中培养三天后的测试结果表明，Opaganib可完全抑制SARS-CoV-2病毒复制，可与此项研究中的阳性对照remdesivir相媲美—Opaganib作为一种潜在的新冠肺炎口服治疗药物，具有独特的优势，它结合有效的抗病毒和抗炎作用机制，靶向宿主细胞成分，并最大限度地降低耐药可能性—采用opaganib治疗重症新冠肺炎的全球2/3期和美国2期临床研究正在进行中—RedHill的第二个治疗新冠肺炎的候选药物RHB-107 (upammostat) 是一种新型丝氨酸蛋白酶抑制剂，它可强烈抑制同一模型中的SARS-CoV-2病毒复制，进一步支持今年晚些时候2/3期美国门诊研究的计划启动以色列特拉维夫和北卡罗来纳罗利, Sept. 11, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL)（以下简称为“ RedHill”或“该公司”）是一家专业生物制药公司，该公司今天宣布，opaganib1显示出可有效抑制导致新冠肺炎的SARS-CoV-2病毒，在人体肺支气管组织的体外模型中完全阻止病毒复制。Opaganib是一种首创的口服鞘氨醇激酶-2 (SK2) 选择性抑制剂，具有双重抗炎和抗病毒活性，靶向宿主细胞成分，不受病毒突变的影响，从而最大限度地降低了耐药可能性。全球2/3期和美国2期临床研究目前正在评估Opaganib治疗重症新冠肺炎的功效。与路易斯维尔大学预测医学中心合作，在一个人体支气管上皮细胞的3D组织模型 (EpiAirway™) 中对Opaganib进行了研究，该模型在形态和功能上类似于人的呼吸道，且与用于发现SARS-CoV-2的模型相似2。该项研究旨在评估opaganib在体外抑制SARS-CoV-2病毒感染的功效，并且包括了已知具有抗病毒活性的remdesivir（瑞德西伟）阳性对照。这项研究结果表明，opaganib对SARS-CoV-2具有明确而令人信服的抗病毒效果。与所有经过测试的化合物相比，包括阳性对照rerestvir，Opaganib表现出最高效活性。对感染SARS-CoV-2的细胞进行治疗，结果表明对病毒产生的抑制取决于剂量，且不会损害细胞膜的完整性（一项衡量细胞生存力和药物安全性的指标），这进一步证明了opaganib治疗新冠肺炎患者的巨大潜力。本新闻稿的随附图表可在以下网址获取：https://www.globenewswire.com/NewsRoom/AttachmentNg/e60ced55-ca9d-4648-81cb-907be7571136培养三天后的测试结果表明，浓度为1...

研究顯示 RedHill Biopharma 的 Opaganib 可全面抑制 SARS-CoV-2

Written by Customer Service on September 10, 2020. Posted in Public Companies.

Opaganib 在人類支氣管組織體外模型中培育三天後，其完全抑制 SARS-CoV-2 病毒複製的測量結果比研究的陽性對照 remdesivir 優勝—Opaganib 是一種獨特口服潛在 COVID-19 治療藥物，結合有效的抗病毒及抗炎作用機制，針對宿主細胞成分並盡量減少抗藥性—全球第 2/3 期及美國第 2 期臨床研究目前正在使用 opaganib 治療嚴重 COVID-19 肺炎 —RedHill 第二種 COVID-19 候選藥物 RHB-107 (upamostat) 是一種新型絲氨酸蛋白酶抑制劑，在同一個模型中強烈抑制 SARS-CoV-2 病毒複製，進一步支援計劃今年稍後啟動的第 2/3 期美國的門診患者研究特拉維夫、以色列及北卡羅萊納州羅利, Sept. 11, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL)（「RedHill」或「公司」）今天宣佈 opaganib1 有效抑制導致 COVID-19 的 SARS-CoV-2 病毒，在人類肺支氣管組織體外模型中完全阻止病毒複製。Opaganib 是一種一流的口服鞘氨醇激酶-2 (SK2) 選擇性抑制劑，具有抗炎及抗病毒活性雙重作用，可針對宿主細胞成分，且不受病毒突變影響，從而盡量降低抗藥性的可能性。Opaganib 目前正在全球第 2/3 期及美國第 2 期臨床研究中接受用於治療嚴重 COVID-19 肺炎的評估。這項與路易斯維爾大學預測醫學中心 (University of Louisville Center for Predictive Medicine) 合作的研究，旨在於人類支氣管上皮細胞 (EpiAirway™) 的 3D 組織模型中對 opaganib 進行研究，模型的形態及功能類似於人類氣道，並與發現 SARS-CoV-22 的模型類似。該研究旨在評估 opaganib...

Opaganib Milik RedHill Biopharma Berhasil Mencegah Replikasi SARS-CoV-2 Sepenuhnya

Written by Customer Service on September 10, 2020. Posted in Public Companies.

Berdasarkan studi inkubasi selama tiga hari dalam model in vitro jaringan bronkial manusia, Opaganib berhasil mencegah replikasi virus SARS-CoV-2 sepenuhnya, sebanding dengan remdesivir sebagai kontrol positif dalam studi tersebut—Opaganib dianggap sebagai satu-satunya obat minum yang berpotensi menyembuhkan COVID-19, menggabungkan mekanisme aksi antivirus dan anti-inflamasi yang ampuh dengan menargetkan komponen sel inang serta meminimalkan kemungkinan resistansi—Opaganib sedang diteliti dalam studi klinis Global Fase 2/3 dan A.S. Fase 2 untuk menyembuhkan pneumonia akut akibat COVID-19 —Kandidat obat COVID-19 berikutnya milik RedHill disebut RHB-107 (upamostat), merupakan serpin baru yang juga berhasil mencegah replikasi virus SARS-CoV-2 pada model yang sama, dan dijadwalkan untuk studi A.S. Fase 2/3 pada pasien rawat...

Day: September 10, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice